To help accelerate biologics development
Altruist Biologics, an Innovent Biologics subsidiary and contract development and manufacturing organisation, has launched Altru-CON- a high-concentration formulation technology platform created to accelerate the development and commercialisation of high-dose biologics. The platform enables protein concentrations up to 200mg/mL and achieves an over two-fold reduction in viscosity.
As the global biologics industry advances toward higher drug concentrations and more patient-friendly delivery formats, Altru-CON delivers breakthroughs in both concentration and stability. Powered by a high-throughput screening approach and an intelligent excipient optimisation system incorporating over 30 excipient combinations, the platform facilitates stable formulations ranging from 100 to 200mg/mL, while maintaining a low viscosity suitable for subcutaneous administration.
High-concentration biologics can pose technical hurdles, including protein-on-protein interactions, viscosity control, and long-term stability, which can complicate manufacturing and increase risks of immunogenicity. The platform’s improved concentration translates into greater flexibility in injection volume, reduced dosing frequency, simplified cold-chain logistics, and improved drug substance and drug product manufacturing efficiency, while shortening IND submission timelines.
Altruist also integrates high-throughput screening of over 40 buffer systems to predict viscosity and aggregation risks. This structured development approach improves candidate selection, reduces late-stage reformulation risk, and improves overall probability of success. So far, Altruist has supported one approved high-concentration product, two late-stage clinical programs, six early-stage clinical programs and 10 preclinical projects.
Dr Kaisong Zhou, chairman and CEO of Altruist Biologics, said, “Altru-CON represents a strategic expansion of our high-concentration formulation capabilities, supporting next-generation biologics from low to ultra-high concentrations with improved stability and viscosity control. Through our integrated drug product formulation experience and client-centric approach, we are committed to supporting our partners accelerate progress and deliver advanced therapies to patients with confidence.”
